Dansk | English
Sitemap
youtube_off.png
linkedin_off.png
Facebook
News

News

  1. Dato
    16.03.2017
  2. BONESUPPORT™ Founder Lars Lidgren Receives the 2017 OREF Clinical Research Kappa Delta Award
  3. The OREF Clinical Research Kappa Delta recognizes outstanding clinical research related directly to musculoskeletal disease or injury. Henrik Malchau, MD, PhD, part of the Swedish and US group, will present the study “Arthroplasty Implant Registries Over The Past Five Decades: Development, Current and Future Impact” The award will be given at the AAOS meeting, San Diego, California on Thursday, March 16 at 11:00 am in the Ballroom 20.

    Lars Lidgren, M.D., Ph.D. Hon. Member AAOS., founder of BONESUPPORT, said: “I’m delighted that clinical research on joint replacements, one of the most common surgical procedures today, has gained this very prestigious award. I am confident that our long term research based on arthroplasty registries will continue to help shape the development of new innovative technologies to provide patients with improved orthopaedic outcomes.”

    - Ends -

    Contact Information

    Citigate Dewe Rogerson

    David Dible, Andrea Bici, Mark Swallow

    +44 (0)20 7282 2949/1050/2948

    bonesupport@citigatedr.co.uk

    Notes to Editor

    About the OREF Clinical Research Kappa Delta Award

    This award recognizes outstanding clinical research related directly to musculoskeletal disease or injury. Eligible applicants must be members of the American Academy of Orthopaedic Surgeons, the Orthopaedic Research Society, the Canadian Orthopaedic Association, and the Canadian Orthopaedic Research Society. The winning paper is presented by the author at the Orthopaedic Research Society's annual meeting, and the award is presented to the recipient by an OREF representative at the Academy's annual meeting during the Kappa Delta Award presentations.

    About BONESUPPORT™

    BONESUPPORT has developed CERAMENT as an innovative range of radiopaque injectable osteoconductive bioceramic products that have a proven ability to heal defects by remodeling to host bone in six to 12 months. Our products are effective in treating patients with fractures and bone voids caused by trauma, infection, disease or related surgery. Our lead product, CERAMENT BONE VOID FILLER (BVF) addresses important issues facing health care providers, such as avoiding hospital readmissions and revision surgery that result from failed bone healing and infection caused by residual bone voids. CERAMENT BVF is commercially available in the U.S., EU, SE Asia and the Middle East.

    CERAMENT’s distinctive properties as a drug eluting material have been validated in clinical practice by CERAMENT G and CERAMENT V, the first CE-marked injectable antibiotic eluting bone graft substitutes. These products provide local sustained delivery of gentamicin and vancomycin, respectively. The local delivery feature enables an initial high concentration of antibiotics to the bone defect and then a longer sustainable dose above the minimal inhibitory concentration (MIC) to protect bone healing and promote bone remodeling.

    CERAMENT G and CERAMENT V have demonstrated good results in patients with problematic bone infections including osteomyelitis. They are also used prophylactically in patients who are at risk for developing infection. CERAMENT G and CERAMENT V are available in the EU.

    BONESUPPORT was founded in 1999 by Prof. Lars Lidgren, an internationally respected scientist who has been the President of various musculoskeletal societies. BONESUPPORT’s mission is to bring people with bone and joint diseases back to an active life. The Company is based in Lund, Sweden. www.bonesupport.com

    BONESUPPORT™ is a registered trademark.

    Billedsamling:
    Kilde: